^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TRAIL R1 agonist

    Related drugs:
    Apply
    A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies (NCT03082209)
    Phase 1
    AbbVie
    Completed
    Last update posted :
    12/09/2022
    Initiation :
    03/20/2017
    Primary completion :
    01/21/2022
    Completion :
    01/21/2022
    KRAS
    |
    KRAS mutation • RAS mutation
    |
    Avastin (bevacizumab) • Venclexta (venetoclax) • 5-fluorouracil • irinotecan • leucovorin calcium • eftozanermin alfa (ABBV-621)
    A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection (NCT03083743)
    Phase 3
    Shanghai Gebaide Biotechnology Co., Ltd.
    Unknown status
    Last update posted :
    03/20/2017
    Initiation :
    10/01/2016
    Primary completion :
    10/01/2017
    Completion :
    06/01/2018
    ALK
    |
    EGFR mutation • ALK positive • ALK mutation • EGFR positive • EGFR negative
    |
    dulanermin (AMG 951)